Trial Profile
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Subjects With Advanced Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Onametostat (Primary)
- Indications Adenoid cystic carcinoma; B-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 10 Oct 2023 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 10 Oct 2023 Planned primary completion date changed from 28 Dec 2023 to 31 Dec 2024.
- 19 Aug 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.